



Express Mail No. EV 475 143 255 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palazzini *et al.*

Serial No.: 09/873,234

Filed: June 4, 2001

For: METHODS AND COMPOSITIONS USING  
SULODEXIDE FOR THE TREATMENT OF  
DIABETIC NEPHROPATHY

Confirmation No.: 4468

Art Unit: 1623

Examiner: Patrick T. Lewis

Attorney Docket No: 9457-023

AMENDMENT FEE TRANSMITTAL SHEET

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying Response of even date herewith concerning the above-identified application has been estimated to be \$0.00.

Please charge any required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: September 27, 2006

Brian M. Poissant 28,462  
Brian M. Poissant (Reg. No.)

By: Henry P. Wu 44,412  
Henry P. Wu (Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
(212) 326-3939



**Express Mail No. EV 475 143 255 US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Palazzini *et al.*

Serial No.: 09/873,234

Filed: June 4, 2001

For: METHODS AND COMPOSITIONS USING  
SULODEXIDE FOR THE TREATMENT OF  
DIABETIC NEPHROPATHY

Confirmation No.: 4468

Art Unit: 1623

Examiner: Patrick T. Lewis

Attorney Docket No.: 9457-023

**RESPONSE UNDER 37 C.F.R. § 1.114 WITH AMENDMENT**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the outstanding Office Action dated August 31, 2005, please enter the amendments and consider the remarks made below, in connection with the above-identified patent application. Submitted concurrently herewith is (a) a Request for Continued Examination; (b) a Declaration of Dr. Robert M. Niecestro under 37 C.F.R. § 1.132; (c) a Petition for an Extension of Time for Response for five (5) months from April 27, 2006 to an including September 27, 2006, accompanied by the appropriate fee; and (d) an Amendment Fee Transmittal Sheet.

**Amendments to the claims** begin on page 2 of this paper.

**Remarks** begin on page 3 of this paper.